PECAM1 and neoplasm: CUR ameliorates NSCLC by reducing tumor size and weight in an ectopic xenograft model, leading to a significant decrease in hemoglobin content, as well as mRNA expression of CD31 and CD105 within the tumor tissue, denoting its antiangiogenic potency.